Key result
Long noncoding RNAs regulate cardiac fibrosis via miRNA sponging, TGF-beta signaling, and exosomal communication.
Why the study?
Cardiac fibrosis remains an unresolved problem in cardiovascular diseases, and lncRNAs have emerged as significant mediators in gene regulation during myocardial fibrosis.
This review synthesizes the molecular mechanisms of long noncoding RNAs—including miRNA sponging, TGF-beta signaling, extracellular matrix regulation, and exosomal transport—in cardiac fibrosis, highlighting their potential and current translational barriers as novel therapeutic targets.
Answers are grounded in this paper and cite their sources.
LncRNA modulation should not yet alter fibrosis management; leaves open therapeutic potential pending clinical trials.
Cardiac fibrosis remains an unresolved problem in cardiovascular diseases. Fibrosis of the myocardium plays a key role in the clinical outcomes of patients with heart injuries. Moderate fibrosis is favorable for cardiac structure maintaining and contractile force transmission, whereas adverse fibrosis generally progresses to ventricular remodeling and cardiac systolic or diastolic dysfunction. The molecular mechanisms involved in these processes are multifactorial and complex. Several molecular mechanisms, such as TGF-β signaling pathway, extracellular matrix (ECM) synthesis and degradation, and non-coding RNAs, positively or negatively regulate myocardial fibrosis. Long noncoding RNAs (lncRNAs) have emerged as significant mediators in gene regulation in cardiovascular diseases. Recent studies have demonstrated that lncRNAs are crucial in genetic programming and gene expression during myocardial fibrosis. We summarize the function of lncRNAs in cardiac fibrosis and their contributions to miRNA expression, TGF-β signaling, and ECMs synthesis, with a particular attention on the exosome-derived lncRNAs in the regulation of adverse fibrosis as well as the mode of action of lncRNAs secreted into exosomes. We also discuss how the current knowledge on lncRNAs can be applied to develop novel therapeutic strategies to prevent or reverse cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Nie et al. (2023) conducted a review in Cardiac fibrosis. Long noncoding RNAs (lncRNAs) was evaluated. Long noncoding RNAs regulate cardiac fibrosis via miRNA sponging, TGF-beta signaling modulation, extracellular matrix synthesis, and exosomal intercellular communication.
Synapse has enriched 10 related papers. Consider them for comparative context: